BioStock - Connecting Innovation & Capital

05/06/2026

Two months after a failed Phase III programme wiped out most of the company's market value, interest is returning – but now in the parts, not the whole. Diamyd Medical announces that it has received a number of external proposals during its ongoing strategic review, including letters of intent and invitations to invest in various projects. At the same time, the company is cutting costs and structuring its work to evaluate the opportunities, with the aim of maximising shareholder value.

Read more at BioStock:

The update should be read against the backdrop of the dramatic share price drop that hit the company during the spring, related to the phase III study DIAGNODE-3 that evaluated retogatein (rhGAD65) in people with newly-onset Stage 3 type 1 diabetes. At the end of March, Diamyd reported that the pred...

05/06/2026

EDITORIAL: Eli Lilly and Boehringer Ingelheim announced this week that they are scaling back their planned investments in Germany by at least one billion dollars each. The trigger is a German reform proposal aimed at pushing down drug prices to reduce the state's healthcare costs. That is a legitimate political goal. But the industry's response is a warning sign Europe should not ignore.

Read more at BioStock: https://biostock.se/en/2026/06/europa-saknar-en-plan-och-big-pharma-borjar-trottna/

05/06/2026

Xspray Pharma has received a Complete Response Letter from the FDA for Nilopki, the company's improved formulation of nilotinib in chronic myeloid leukaemia. The FDA is unable to approve the application at this time and has identified three specific issues that need to be addressed. A launch of Nilopki in 2026 is now considered unlikely.

Read more at BioStock: https://biostock.se/en/2026/06/fda-bromsar-nilopki-godkannandet-for-xspray-pharma/

04/06/2026

Annexin Pharmaceuticals AB (publ) tar in 20 Mkr för fas IIa-studie inom ögonsjukdomar
Annexin Pharmaceuticals ska säkra finansieringen av sin pågående NEXUS-studie fram till årsskiftet genom en företrädesemission. Befintliga huvudägare, styrelse och ledning visar starkt stöd och har redan förbundit sig att teckna cirka 60 procent av beloppet.
De kliniska data som genereras i studien är helt centrala i bolagets pågående diskussioner med potentiella partners, där det uttalade målet är att ingå ett licensavtal under året. Initiala effektsignaler har hittills varit gynnsamma, och en uppdatering väntas före slutet av juni.
Läs hela artikeln för detaljer om villkor, tidsplan och den senaste utvecklingen.

Annexin utvecklar läkemedelskandidaten ANXV, ett rekombinant protein med potential att bli ett first-in-class läkemedel mot sjukdomar kopplade till inflammation och skador i blodkärlen. Till skillnad från befintliga behandlingar, som i huvudsak lindrar symtom, är ambitionen att ANXV ska kunna a...

04/06/2026

Biotech company Circio is currently conducting a warrant program with the goal of raising approximately NOK 300 million. The capital will, among other things, support the company's next major milestones and the continued development of the circular RNA platform circVec. BioStock spoke with CEO Erik Digman Wiklund and CFO and Head of Business Development Lubor Gaal to discuss the strong investor interest, the latest preclinical advances in gene therapy, and the company's global partner strategy.

See the full interview with Circio's CEO Erik Digman Wiklund and CFO and Head of Business Development Lubor Gaal below.

04/06/2026

📬 Dagens Nyhetssvep från BioStock!
🔹 Xbrane Biopharma AB har erhållit ett FDA-beslutsdatum (BsUFA) till den 29 oktober 2026 för sin biosimilarkandidat till Lucentis.
🔹 DexTech Medical meddelar att bolagets myelomstudie är färdigrekryterad och beskriver de preliminära resultaten som mycket positiva.
🔹 BrainCool har erhållit marknadsgodkännande i Taiwan.

Håll dig uppdaterad – läs hela Svepet hos BioStock.

AcouSort får order på AcouWash från bolag inom veterinärdiagnostik. Läs mer. Annexin Pharmaceuticals beslutar om en företrädesemission om cirka 20 Mkr, säkerställd till cirka 60 procent, med en övertilldelningsoption om upp till cirka 5 Mkr. Läs mer. BrainCool erhåller marknadsgodkännan...

04/06/2026

DexTech Medical's clinical study of OsteoDex in myeloma is fully recruited and the preliminary results are positive. All patients transitioned from progressive to non-progressive disease during treatment, and more than 70 per cent maintained their achieved stable disease even after treatment was discontinued.

Read more at BioStock:

Uppsala-based DexTech Medical is developing drug candidates based on its technology platform, with OsteoDex as the lead candidate. The company has previously conducted a phase II study with OsteoDex in castration-resistant prostate cancer with bone metastases, and is now evaluating the candidate in....

04/06/2026

A new study published in The Journal of Bone and Mineral Research shows that OssDsign Catalyst heals critical bone defects twice as fast as synthetic bone substitutes of an older generation, and that the graft is gradually resorbed and replaced by the body's own bone. The news sent the share price sharply higher on Wednesday.

Read more at BioStock:

Uppsala-based OssDsign develops orthobiological products that support the body’s own healing ability. The company’s flagship product Catalyst is a CE-marked and FDA-approved nanosynthetic bone substitute, used in spinal surgery and cranial reconstruction, among other things. In the current study...

03/06/2026

AcouSort has received an order worth USD 59 from a large US-based veterinary diagnostics company. The order covers an AcouWash system to be used in the customer's R&D operations.

Read more at BioStock:

Lund-based AcouSort develops products for automated handling and separation of biological samples using acoustofluidics – a technology where ultrasound waves in combination with microfluidics enable controlled separation of cells, bacteria and particles. The company’s products are used in proces...

03/06/2026

Eli Lilly has entered into a collaboration agreement with China's Haisco Pharmaceutical worth up to USD 3 billion. The deal spans up to five programmes across multiple therapeutic areas – but the details are being kept under wraps.

Read more at BioStock:

Lilly has been in an intense acquisition mode in recent months, driven by the enormous cash flows generated by the weight loss drug Zepbound. This year's purchase list includes a pair of in vivo CAR-T companies, three vaccine companies and the JAK inhibitor biotech company Ajax Therapeutics. Now a C...